ELV

Elevance Health Inc. Healthcare - Insurance Investor Relations →

NO
4.7% ABOVE
↑ Moving away Was 3.7% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $410.42
14-Week RSI 62
Rel. Volume (14w) This week's trading vs. the 14-week average 0.9x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.07

Elevance Health Inc. (ELV) closed at $429.69 as of 2026-11-13, trading 4.7% above its 200-week moving average of $410.42. The stock moved further from the line this week, up from 3.7% last week. The 14-week RSI sits at 62, indicating neutral momentum.

Trading volume is running at 0.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.07 ratio) is neutral — neither side is clearly dominating.

Over the past 1258 weeks of data, ELV has crossed below its 200-week moving average 10 times. On average, these episodes lasted 26 weeks. Historically, investors who bought ELV at the start of these episodes saw an average one-year return of +23.1%.

With a market cap of $92.8 billion, ELV is a large-cap stock. The company generates a free cash flow yield of 8.6%, which is notably high. Return on equity stands at 11.5%. The stock trades at 2.1x book value.

The company has been aggressively buying back shares, reducing its share count by 7.2% over the past three years.

Over the past 24.2 years, a hypothetical investment of $100 in ELV would have grown to $1720, compared to $1318 for the S&P 500. That represents an annualized return of 12.5% vs 11.3% for the index — confirming ELV as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

In the past 12 months, corporate insiders have made 3 open-market purchases totaling $2,237,800.

Free cash flow has been declining at a -24.1% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: ELV vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After ELV Crosses Below the Line?

Across 10 historical episodes, buying ELV when it crossed below its 200-week moving average produced an average return of +31.8% after 12 months (median +43.0%), compared to +22.1% for the S&P 500 over the same periods. 80% of those episodes were profitable after one year. After 24 months, the average return was +77.2% vs +37.8% for the index.

Each line shows $100 invested at the moment ELV crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices ELV would reach each dislocation threshold.

Current Bean Score -1.44σ
Current FCF Yield 7.02%
Baseline Yield 7.80%
Historical σ 0.57pp

Dislocation Price Levels

Prices where ELV's Bean Score would hit each σ threshold. Valid until next earnings report: 2027-01-28.

LevelσPriceSignal
Deep Value+2σ$336.22Unusually cheap — analysis point
Value+1σ$358.89Cheap vs. own history
Fair Value+0σ$384.84Historical mean behavior
Expensive-1σ$414.83Expensive vs. own history
Deep Expensive-2σ$449.89Unusually expensive — analysis point

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Recent Earnings

DateEPS Est.EPS ActualSurprise
2026-10-21$4.69$6.99+48.9%
2026-07-15$6.21$7.45+20.0%
2026-04-22$10.81$12.58+16.4%
2026-01-28$3.09$3.33+7.7%
Data depth: 2 quarterly baselines, 19 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

21 / 13 weeks minimum

the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from ELV's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation +0.60σ Dividend yield vs own 10-yr norm
Drawdown Score +0.69σ Distance from line vs own history
Sector-Relative N/A Vs sector median this week
Buyback Acceleration -0.5pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity 25th TTM buys / market cap, percentile of buyers
FCF Yield vs History +3.4pp Vs own recent annual mean
Earnings Quality Stable Accrual gap trend (+1.1pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Insider Buying Activity

1 conviction buy in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2026-03-05COLLIS STEVEN HOWARDDirector$869,5203,000N/A

Historical Touches

ELV has crossed below its 200-week MA 10 times with an average 1-year return of +23.1% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Nov 2002Dec 200222.0%+14.7%+1735.9%
Jan 2003Jan 200310.3%+21.8%+1707.9%
Feb 2003Mar 2003610.1%+44.1%+1787.3%
Mar 2008Jan 20109657.2%-53.2%+712.9%
Feb 2010Mar 201066.9%+5.5%+784.5%
Apr 2010Jan 20113922.5%+13.0%+790.7%
Jul 2012Aug 201222.9%+57.1%+866.9%
Nov 2012Dec 201254.9%+58.6%+844.3%
Mar 2020Apr 2020312.5%+87.3%+145.9%
Oct 2024Oct 202610339.0%-17.6%+3.6%
Average26—+23.1%—

Frequently Asked Questions

Is ELV below its 200-week moving average?

No. Elevance Health Inc. (ELV) is currently 4.7% above its 200-week moving average of $410.42. It would need to fall to $410.42 to cross below the line.

What is ELV's 200-week moving average price?

Elevance Health Inc.'s 200-week moving average is $410.42 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when ELV drops below its 200-week moving average?

ELV has crossed below its 200-week moving average 10 times in our data. On average, buying at that moment produced a one-year return of +23.1%. These dips have historically been decent entry points. These episodes lasted 26 weeks on average.

Is ELV a good value right now?

Here's what our data says about ELV as of 2026-11-13: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 62. Free cash flow yield is 8.6%. Return on equity is 11.5%. Price-to-book is 2.1x. This is not a buy or sell recommendation — always do your own research.

How does ELV compare to the S&P 500?

Over the past 24.2 years, $100 invested in ELV would have grown to $1720, compared to $1318 for the S&P 500. That's 12.5% annualized vs 11.3% for the index. ELV has outperformed the broader market over this period.

Does ELV pay a dividend?

Yes. Elevance Health Inc. currently pays a dividend yield of 160.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13